Eisai Company, Ltd. Receives Orphan Drug Designation for Anticancer Agent Lenvatinib in Japan

Published: Aug 20, 2012

Tokyo, Aug 20, 2012 (JCN Newswire) - Eisai Co., Ltd. announced today that it has received orphan drug designation from Japan's Ministry of Labour, Health and Welfare for its multikinase inhibitor lenvatinib mesylate ("lenvatinib") for the treatment of thyroid cancer, the drug's prospective indication.

Back to news